As a leading enterprise in the field of biotechnology, Creative Biolabs takes great pride in offering the academic community a comprehensive range of services related to high-affinity bispecific antibodies (BsAbs). Leveraging our state-of-the-art and robust BsAb platform, we provide a sophisticated, all-in-one solution encompassing design, manufacture, and analysis for diverse applications across various domains.
Bispecific antibodies (bsAbs) have drawn great attention owing to their capability of simultaneous binding to two or even more antigenic epitopes. The development of antibody technologies makes bsAb advance swiftly and vigorously. Up to now, four bsAb drugs have been approved for the treatment of human diseases, including age-related macular degeneration, non-small cell lung cancer, lymphocytic leukemia, and Haemophilia A. Since the first emergence in the 1970s, a variety of bsAb formats have been developed, covering small molecules that consist of only two linked antigen-binding fragments to large proteins like engineered IgGs. The bsAb holds great immune-therapeutic promise attributed to the diversity of formats, targets, and mechanisms.
Fig 1. Timeline of the development of bsAbs.1
| Application of BsAbs in Oncology | BsAbs have demonstrated remarkable potential in interfering with critical signaling pathways within the field of tumor pathology. They can effectively disrupt these pathways or recruit/redirect cytotoxic immune cells to eradicate tumors. Creative Biolabs offers top-tier services in designing and engineering BsAbs that facilitate signal pathway interference, payload delivery, and immune cell recruitment, catering to the specific requirements of oncology applications. |
| Application of BsAbs in Immunology | The dysregulation of immune responses often leads to tissue damage and the development of severe diseases. Extensive research has substantiated the invaluable applications of BsAbs in immunology, as they possess the capability to interfere with receptor signaling, thereby influencing a wide array of immune-related conditions. |
| Application of BsAbs in Hematology | BsAbs have already exhibited promising results in addressing hematological disorders that impact blood components or give rise to coagulation issues. By intervening in the pathological processes underlying these blood cancers, BsAbs offer a viable therapeutic approach. |
| Application of BsAbs in Ophthalmology | Numerous diseases are intricately linked to vascular abnormalities, such as vision changes resulting from abnormal retinal or choroidal neovascularization. BsAbs have emerged as the optimal pharmaceutical format for tackling vision loss, thus representing the next generation of therapeutic interventions. Creative Biolabs is dedicated to providing dependable BsAb purification services that cater to your specific requirements in drug development. |
| Application of BsAbs in Orthopedics | In the field of bone research, BsAbs present a potential strategy by facilitating protein associations. Currently, BsAbs designed to target RANKL itself and the RANKL/RNAK signaling pathway have been successfully generated, thereby safeguarding bone remodeling and intervening in malignant orthopedic diseases. |
| Application of BsAbs in Pulmonary and Respiratory System Diseases | Infections and inflammation are the primary mechanisms underlying pulmonary and respiratory system diseases. Some of these conditions are exacerbated by unwanted immune responses, excessive inflammation, or abnormal wound-healing processes. BsAbs possess the ability to bind ligands or receptors, effectively blocking unnecessary signaling pathways, and thus hold promise for the treatment of pulmonary and respiratory system disorders. |
| Application of BsAbs in Pre-targeting Systems | The unique characteristic of BsAbs lies in their ability to simultaneously bind multiple antigens/receptors or combine different targets into a single entity. This versatility renders BsAbs highly suitable for the delivery and payload of various drugs, radiolabels, or other small molecules. Particularly within the context of cancer intervention, tumor-targeting BsAbs can facilitate the delivery of cytotoxic radiation to malignant cells. |
| Application of BsAbs in Diagnostics | BsAbs play a pivotal role in achieving heightened sensitivity, rapidity, and specificity in diagnostic procedures. By utilizing BsAb diagnostic reagents, batch variations can be effectively circumvented. Moreover, BsAb-mediated reactions enhance the signal-to-noise ratio of immunodiagnostic tests, significantly streamlining the overall process. |
| Application of BsAbs in Gene Therapy | BsAbs can serve as therapeutic genes, either through transfer or as adapter molecules. This enables the transfer of human genes for gene correction or the introduction of genes from different species to facilitate disease intervention objectives. |
Fig 2. Mechanisms of action enabled by BsAbs.2
| Paper Title | A novel bispecific antibody, BiSS, with potent anti-cancer activities |
| Journal | Cancer Biology & Therapy |
| Published | 2016 |
| Abstract | Bispecific antibodies (BsAbs) have the potential to recruit immune cells to kill cancer cells, effectively intervening in the pathological processes of cancer. However, most existing forms of BsAbs have various limitations. In this study, researchers proposed a novel type of BsAb called Bispecialantibody with Singledomain by linking anti-CEA and anti-CD16 single-domain antibodies. Unlike traditional BsAbs, this novel antibody can be expressed and purified in large quantities directly from Escherichia coli, achieving cell killing and cancer intervention by recruiting immune cells to CEA-positive cancer cells. Research data indicate that single-domain-based BsAbs exhibit excellent functionality and recognition ability, making them a promising strategy for cancer intervention. |
| Result |
In this study, researchers constructed BsAbs by linking two single-domain antibodies and confirmed their characteristics as single-domain antibodies. The BsAbs can be expressed and purified directly from Escherichia coli, demonstrating good solubility and stability. Furthermore, the BsAbs have a lower molecular weight and better stability. The study demonstrated that the BsAbs specifically target CD16 on NK cells and the cancer marker CEA, and exhibit effective cytotoxicity against CEA-positive cancer cells even at low concentrations. In conclusion, the researchers synthesized a novel BsAb by combining two single-domain antibodies and validated its potential advantages compared to other antibodies, positioning it as a promising intervention drug for CEA-positive cancer.
Fig. 3 Cell death of CEA-positive cancer cells.3 |
Creative Biolabs is dedicated to delivering the utmost reliable services in the field of BsAbs to our esteemed customers. Our comprehensive range of services encompasses customized BsAb design, manufacture, analysis, engineering, and purification services. With our profound expertise and state-of-the-art technical platforms, we are fully equipped to cater to all your research requirements and elevate the outcomes of your investigations. We encourage you to reach out to us without any hesitation to explore further information and avail yourself of our exceptional services.
References
1. Labrijn, Aran F., et al. "Bispecific antibodies: a mechanistic review of the pipeline." Nature reviews Drug discovery. 18.8 (2019): 585-608.
2. Husain and Ellerman. "Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies. " BioDrugs. 32 (2018): 441-464.
3. Dong, Zhou, et al. "A novel bispecific antibody, BiSS, with potent anti-cancer activities. " Cancer Biology & Therapy. 17,4 (2016): 364-370
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
